Research programme: depression therapy - Neurologix

Drug Profile

Research programme: depression therapy - Neurologix

Latest Information Update: 06 Jun 2014

Price : $50

At a glance

  • Originator Cornell University
  • Developer Cornell University; Neurologix
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 16 Mar 2012 Discontinued - Preclinical for Major depressive disorder in USA (Parenteral)
  • 28 Apr 2011 This programme is in active development
  • 27 Oct 2009 Preclinical trials in Depression in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top